The Federal Circuit has denied requests for a rehearing from both parties involved in a case related to the drug Xifaxan. This decision stems from an April ruling that prohibits an Alvogen unit from launching a generic version of Bausch Health’s medication, which is used to treat diarrhea and brain disorders, until 2029. The impact of this ruling extends the exclusivity period for Bausch Health’s drug, affecting the generic pharmaceutical landscape.
For further details, the original article is accessible here.